Cancer Genetics (CGIX) Tops Q1 EPS by 4c

Cancer Genetics (NASDAQ: CGIX) reported Q1 EPS of ($0.39), $0.04 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $6.95 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Tenon Medical (TNON) Misses Q2 EPS by 395c
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c